TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07813637: Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

Sponsor: Janux Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 110 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07813637 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07813637 Rescue Dossier →